檢索結果 - Sith Sathornsumetee

  • Showing 1 - 19 results of 19
Refine Results
  1. 1
    Twisted tango: brain tumor neurovascular interactions

    Twisted tango: brain tumor neurovascular interactions 由 Anita B. Hjelmeland, Justin D. Lathia, Sith Sathornsumetee, Jeremy N. Rich

    出版 2011
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Molecularly targeted therapy for malignant glioma

    Molecularly targeted therapy for malignant glioma 由 Sith Sathornsumetee, David A. Reardon, Annick Desjardins, Jennifer A. Quinn, James J. Vredenburgh, Jeremy N. Rich

    出版 2007
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Targeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth

    Targeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth 由 Shideng Bao, Qiulian Wu, Zhizhong Li, Sith Sathornsumetee, Hui Wang, Roger E. McLendon, Anita B. Hjelmeland, Jeremy N. Rich

    出版 2008
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

    Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma 由 David A. Reardon, James J. Vredenburgh, April Coan, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, Sith Sathornsumetee, Jeremy N. Rich, James E. Herndon, Henry S. Friedman

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor

    Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor 由 Shideng Bao, Qiulian Wu, Sith Sathornsumetee, Yueling Hao, Zhizhong Li, Anita B. Hjelmeland, Qing Shi, Roger E. McLendon, Darell D. Bigner, Jeremy N. Rich

    出版 2006
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

    Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan 由 Sith Sathornsumetee, Yiting Cao, Jennifer Marcello, James E. Herndon, Roger E. McLendon, Annick Desjardins, Henry S. Friedman, Mark W. Dewhirst, James J. Vredenburgh, Jeremy N. Rich

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.

    SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. 由 Mark D. Hjelmeland, Anita B. Hjelmeland, Sith Sathornsumetee, Elizabeth D. Reese, Michael H. Herbstreith, Nicholas J. Laping, Henry S. Friedman, Darell D. Bigner, Xiao-Fan Wang, Jeremy N. Rich

    出版 2004
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility

    SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility 由 Mark D. Hjelmeland, Anita B. Hjelmeland, Sith Sathornsumetee, Elizabeth D. Reese, Michael H. Herbstreith, Nicholas J. Laping, Henry S. Friedman, Darell D. Bigner, Xiao‐Fan Wang, Jeremy N. Rich

    出版 2004
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells

    Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells 由 Zhizhong Li, Shideng Bao, Qiulian Wu, Hui Wang, Christine E. Eyler, Sith Sathornsumetee, Qing Shi, Yiting Cao, Justin D. Lathia, Roger E. McLendon, Anita B. Hjelmeland, Jeremy N. Rich

    出版 2009
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

    Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma 由 Sith Sathornsumetee, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, Jennifer Marcello, James E. Herndon, Alyssa Mathe, Marta Hamilton, Jeremy N. Rich, J. Norfleet, Sridharan Gururangan, Henry S. Friedman, David A. Reardon

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

    Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study 由 David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Sith Sathornsumetee, Roger E. McLendon, James E. Herndon, Jennifer Marcello, J. Norfleet, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

    Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma 由 James J. Vredenburgh, Annick Desjardins, James E. Herndon, Jeannette M. Dowell, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, Melissa Wagner, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman

    出版 2007
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

    Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas 由 Annick Desjardins, David A. Reardon, James E. Herndon, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, John H. Sampson, Leighann Bailey, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman, James J. Vredenburgh

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

    Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme 由 James J. Vredenburgh, Annick Desjardins, James E. Herndon, Jennifer Marcello, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, John H. Sampson, Melissa Wagner, Leighann Bailey, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman

    出版 2007
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors

    ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumo... 由 Jeremy N. Rich, Sith Sathornsumetee, Stephen T. Keir, Mark W. Kieran, Andrea Laforme, Arja Kaipainen, Roger E. McLendon, Michael W. Graner, Binish Rasheed, Xuan Wang, David A. Reardon, Anderson J. Ryan, Catherine Wheeler, Isaiah W. Dimery, Darell D. Bigner, Henry S. Friedman

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

    Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients 由 David A. Reardon, James E. Herndon, Katherine B. Peters, Annick Desjardins, April Coan, Emil Lou, Ashley Sumrall, Scott Turner, Eric Lipp, Sith Sathornsumetee, Jeremy N. Rich, John H. Sampson, Allan H. Friedman, Susan Boulton, Darell D. Bigner, Henry S. Friedman, James J. Vredenburgh

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

    Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma 由 David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Sith Sathornsumetee, Michael Badruddoja, Roger E. McLendon, James Provenzale, James E. Herndon, Jeannette M. Dowell, Jill L. Burkart, Herbert B. Newton, Allan H. Friedman, Henry S. Friedman

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme

    Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme 由 David A. Reardon, Merrill J. Egorin, Jennifer A. Quinn, Jeremy N. Rich, Idharan Gururangan, James J. Vredenburgh, Annick Desjardins, Sith Sathornsumetee, James M. Provenzale, James E. Herndon, Jeannette M. Dowell, Michael Badruddoja, Roger E. McLendon, Theodore Lagattuta, Kimberly Kicielinski, G. Dresemann, John H. Sampson, Allan H. Friedman, August J. Salvado, Henry S. Friedman

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Oligosarcomas, IDH-mutant are distinct and aggressive

    Oligosarcomas, IDH-mutant are distinct and aggressive 由 Abigail K. Suwala, Marius Felix, Dennis Friedel, Damian Stichel, Daniel Schrimpf, Felix Hinz, Ekkehard Hewer, Leonille Schweizer, Hildegard Dohmen, Ute Pohl, Ori Staszewski, Andrey Korshunov, Marco Stein, Thidathip Wongsurawat, Pornsuk Cheunsuacchon, Sith Sathornsumetee, Christian Koelsche, Clinton Turner, Émilie Le Rhun, Angelika Mühlebner, Philippe Schucht, Koray Özduman, Takahiro Ono, Hiroaki Shimizu, Marco Prinz, Till Acker, Christel Herold‐Mende, Tobias Keßler, Wolfgang Wick, David Capper, Pieter Wesseling, Felix Sahm, Andreas von Deimling, Christian Hartmann, David Reuß

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: